Observational studyAsian Pacific journal of cancer prevention : APJCP2026
Predictive Value of Serum MTHFR and CEA Levels for Tumor Size Reduction Following Neoadjuvant CAPEOX Therapy in Advanced Colorectal Cancer Patients in Makassar.
Observational study in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate the predictive value of serum levels of methylenetetrahydrofolate reductase (MTHFR) and carcinoembryonic antigen (CEA) for tumor size reduction following neoadjuvant CAPEOX chemotherapy in patients with advanced colorectal cancer.
methodsA prospective observational study was conducted involving 36 patients with histologically confirmed stage III-IV colorectal cancer who underwent neoadjuvant CAPEOX therapy. Serum MTHFR and CEA levels were measured before chemotherapy. Tumor response was assessed by comparing pre- and post-treatment imaging, based on RECIST criteria. Correlations between the biomarkers and the percentage of tumor reduction were analyzed using Spearman's test, followed by multivariate linear regression to develop a predictive model.
resultsThe mean age of participants was 45.6 ± 8.0 years, with a predominance of male patients (66.7%). Both serum MTHFR and CEA levels showed significant correlations with tumor size reduction (MTHFR: ρ = 0.764, p < 0.001; CEA: ρ = 0.654, p < 0.001). The final regression model demonstrated strong predictive performance: Tumor size reduction (%) = -165.68 + (1.10 × CEA) + (15.38 × MTHFR), with an adjusted R² of 0.714 (p < 0.001). A nomogram derived from this model yielded a Harrell's C-index of 0.836, indicating high discriminative ability in predicting therapeutic response.
conclusionSerum MTHFR and CEA levels serve as complementary biomarkers for predicting tumor size reduction following neoadjuvant CAPEOX chemotherapy in advanced colorectal cancer. Their combined use provides a simple, cost-effective tool for individualized treatment planning and advances biomarker-based precision oncology in resource-limited clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.